637 reports of this reaction
2.4% of all DOCOSANOL reports
#7 most reported adverse reaction
INCORRECT PRODUCT ADMINISTRATION DURATION is the #7 most commonly reported adverse reaction for DOCOSANOL, manufactured by Haleon US Holdings LLC. There are 637 FDA adverse event reports linking DOCOSANOL to INCORRECT PRODUCT ADMINISTRATION DURATION. This represents approximately 2.4% of all 26,055 adverse event reports for this drug.
Patients taking DOCOSANOL who experience incorrect product administration duration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INCORRECT PRODUCT ADMINISTRATION DURATION is a less commonly reported adverse event for DOCOSANOL, but still significant enough to appear in the safety profile.
In addition to incorrect product administration duration, the following adverse reactions have been reported for DOCOSANOL:
The following drugs have also been linked to incorrect product administration duration in FDA adverse event reports:
INCORRECT PRODUCT ADMINISTRATION DURATION has been reported as an adverse event in 637 FDA reports for DOCOSANOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
INCORRECT PRODUCT ADMINISTRATION DURATION accounts for approximately 2.4% of all adverse event reports for DOCOSANOL, making it a notable side effect.
If you experience incorrect product administration duration while taking DOCOSANOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.